A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
about
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to dateDeregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsIt is time to include patients with brain tumors in phase I trials in oncologyPhase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.Experimental approaches for the treatment of malignant gliomas.The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.Supramolecular Probes for Assessing Glutamine Uptake Enable Semi-Quantitative Metabolic Models in Single Cells.Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas.Epilepsy in the cancer patient.Medical treatment of recurrent meningiomas.Role of tyrosine kinase inhibitors in the management of high-grade gliomas.Enzyme induction with antiepileptic drugs: cause for concern?Targeted therapy in gliomas.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Glioblastoma multiforme: State of the art and future therapeutics.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Issues in developing drugs for primary brain tumors: barriers and toxicities.Emerging Medical Treatments for Meningioma in the Molecular Era
P2860
Q26822717-19429469-674B-42A0-9BBF-60A34C80C97EQ26829873-6E8ECB96-7E25-47AE-B77B-F87AAD05BB27Q30359570-E2EA478D-9DF2-49C2-852D-F72566344597Q30361848-8E87CD06-2902-424F-8C3E-76007997F80CQ30393860-F4100E14-9F98-476A-B9EF-08648EEC980CQ34127138-C34672AC-9425-4C33-BDEB-60349DCA4533Q34468816-E253BD81-96C2-4EC3-96C8-D453FFE263F3Q34778047-1D4E77A0-85FC-4D41-87F2-24FDA2B1A268Q35936244-7A78B49F-082C-4028-8360-02654AEB3A5FQ36072027-53791EF5-F260-4BB3-A85E-126905DEE6FEQ36682422-89FC6286-6CB6-4858-AEB6-BD3891668580Q36713494-C4FD20A7-6BE4-44D8-B81C-E96991BF9FFDQ37689492-AFF09D73-11CF-48C1-A3A2-A43E3014C06AQ37838314-4B4D3B2C-2315-40A3-B3DD-59CE1BE4BEBAQ37939997-A900ACB4-78DE-48D5-906B-8EF5EE557294Q37952242-5D88EFF8-EED2-451E-829B-740902455396Q38046892-E3E2F145-D01B-4E58-A5F6-A6CDB77AF6E9Q38186656-87511296-A855-4D7D-978E-5A8BC9AED5D1Q38190857-5436D4DE-A77E-44B2-A1A2-AEA2E5FF447DQ38225874-F5C6DCF3-34AE-4CDB-815E-AFBBD0C679B4Q47969048-FB788399-CC55-4DAE-9E4E-29B34F7EDF2FQ50435642-1E10ABDD-A4DA-4E47-ADDF-200C85B35A67Q58798211-9E48E9C5-6A47-4577-94A3-3B874E1AD597
P2860
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase I trial of erlotinib i ...... gnant gliomas and meningiomas.
@ast
A phase I trial of erlotinib i ...... gnant gliomas and meningiomas.
@en
A phase I trial of erlotinib i ...... gnant gliomas and meningiomas.
@nl
type
label
A phase I trial of erlotinib i ...... gnant gliomas and meningiomas.
@ast
A phase I trial of erlotinib i ...... gnant gliomas and meningiomas.
@en
A phase I trial of erlotinib i ...... gnant gliomas and meningiomas.
@nl
prefLabel
A phase I trial of erlotinib i ...... gnant gliomas and meningiomas.
@ast
A phase I trial of erlotinib i ...... gnant gliomas and meningiomas.
@en
A phase I trial of erlotinib i ...... gnant gliomas and meningiomas.
@nl
P2093
P2860
P356
P1433
P1476
A phase I trial of erlotinib i ...... ignant gliomas and meningiomas
@en
P2093
Andrew B Lassman
Frank Lieberman
H Ian Robins
Howard A Fine
Janet Dancey
Jeffrey J Raizer
John G Kuhn
Kathleen R Lamborn
Kenneth D Aldape
Lauren E Abrey
P2860
P356
10.1093/NEUONC/NOP017
P577
2009-12-14T00:00:00Z